Theracryf (LON:TCF – Get Free Report) issued its quarterly earnings results on Monday. The company reported GBX (0.16) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Theracryf had a negative return on equity of 37.30% and a negative net margin of 792.17%.
Theracryf Price Performance
Theracryf stock opened at GBX 0.18 on Monday. The stock has a market capitalization of £3.87 million, a price-to-earnings ratio of -1.38 and a beta of 1.37. Theracryf has a 1-year low of GBX 0.16 and a 1-year high of GBX 0.27. The business has a fifty day moving average price of GBX 0.19 and a 200-day moving average price of GBX 0.21.
Theracryf Company Profile
The Group’s lead programme is a novel, best-in-class orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol and other substance use disorders. The programme is heavily de-risked, demonstrates superior selectivity and high receptor occupancy, and is fully funded through to clinical readiness, with regulatory submissions targeted for 2026.
TheraCryf also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy and narcolepsy.
Read More
- Five stocks we like better than Theracryf
- 3 Niche Growth Stocks With an Edge Their Rivals Can’t Ignore
- 3 Dividend Stocks With Higher Yields and Room for More Payout Growth
- Data Centers Got the AI Hype—But Office REITs May Get the Rent Hikes
- 2 Cybersecurity Stocks Breaking Out as AI Continues to Be a Tailwind
Receive News & Ratings for Theracryf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theracryf and related companies with MarketBeat.com's FREE daily email newsletter.
